BiomX logo

BiomXNYSE American: PHGE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

13 March 2019

Next earnings report:

03 April 2025

Last dividends:

N/A

Next dividends:

N/A
$9.68 M
-84%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector
-95%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 23:25:29 GMT
$0.53-$0.03(-4.95%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PHGE Latest News

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
globenewswire.com12 November 2024 Sentiment: POSITIVE

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.

BiomX Announces a Mandatory Unit Separation
globenewswire.com15 October 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the “Units”). Each warrant (a “Warrant”) entitles the holder to purchase one-half of a share of Common Stock at price of $115 per share.

BiomX Stock Gains From Favorable Study Data Presentation on BX004
zacks.com20 September 2024 Sentiment: POSITIVE

PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept.

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
globenewswire.com18 September 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections.

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
globenewswire.com04 September 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
globenewswire.com16 August 2024 Sentiment: NEUTRAL

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
globenewswire.com15 August 2024 Sentiment: POSITIVE

BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading pha ge therap y pipeline

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
globenewswire.com10 July 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company's stockholders have voted to approve a proposal to convert BiomX's outstanding Series X Non-Voting Convertible Preferred Stock (“Series X Preferred Stock”) into shares of BiomX's common stock. The result of the vote was previously disclosed in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on July 9, 2024.

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
globenewswire.com30 May 2024 Sentiment: NEGATIVE

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification (“the Notice”) from the NYSE American LLC (“NYSE American”), dated May 23, 2024, stating that the Company is no longer in compliance with continued listing standards, as set forth in Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”).

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
globenewswire.com30 May 2024 Sentiment: POSITIVE

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present at two upcoming conferences data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in an oral presentation and an ePoster at the 47th European Cystic Fibrosis Conference, which is taking place June 5-8, 2024, in Glasgow, United Kingdom, and in a Rapid Fire oral presentation and a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-17, 2024, in Atlanta, Georgia.

What type of business is BiomX?

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

What sector is BiomX in?

BiomX is in the Healthcare sector

What industry is BiomX in?

BiomX is in the Biotechnology industry

What country is BiomX from?

BiomX is headquartered in Israel

When did BiomX go public?

BiomX initial public offering (IPO) was on 13 March 2019

What is BiomX website?

https://www.biomx.com

Is BiomX in the S&P 500?

No, BiomX is not included in the S&P 500 index

Is BiomX in the NASDAQ 100?

No, BiomX is not included in the NASDAQ 100 index

Is BiomX in the Dow Jones?

No, BiomX is not included in the Dow Jones index

When was BiomX the previous earnings report?

No data

When does BiomX earnings report?

The next expected earnings date for BiomX is 03 April 2025